Sana Biotechnology (SANA) EPS (Weighted Average and Diluted) (2020 - 2026)
Sana Biotechnology recorded quarterly EPS (Weighted Average and Diluted) of -$0.17 in Q1 2026, up 19.05% quarter-over-quarter from -$0.21 in Q4 2025, and up 19.05% year-over-year from -$0.14 in Q1 2025.
Sana Biotechnology's EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$0.17 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 19.05% year-over-year to -$0.17; the TTM figure through Mar 2026 stood at -$0.93 (down 5.68% YoY), while the FY2025 annual figure was -$0.96, up 17.24% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.17 for Q1 2026 at Sana Biotechnology, up from -$0.21 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.16 in Q3 2025 to a low of -$0.59 in Q2 2023.
- A 5-year average of -$0.32 and a median of -$0.32 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) plunged 533.33% in 2022 and jumped 64.41% in 2024, its largest moves.
- Sana Biotechnology's EPS (Weighted Average and Diluted) stood at -$0.42 in 2022, then declined by 7.14% to -$0.45 in 2023, then jumped by 53.33% to -$0.21 in 2024, then changed by 0.0% to -$0.21 in 2025, then increased by 19.05% to -$0.17 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.17, -$0.21, and -$0.16 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - | -0.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.17 |
| Dec 31, 2025 | -0.21 |
| Sep 30, 2025 | -0.16 |
| Jun 30, 2025 | -0.39 |
| Mar 31, 2025 | -0.21 |
| Dec 31, 2024 | -0.21 |
| Sep 30, 2024 | -0.25 |
| Jun 30, 2024 | -0.21 |
| Mar 31, 2024 | -0.49 |
| Dec 31, 2023 | -0.45 |
| Jun 30, 2023 | -0.59 |
| Mar 31, 2023 | -0.43 |
| Dec 31, 2022 | -0.42 |
| Sep 30, 2022 | -0.45 |
| Jun 30, 2022 | -0.39 |
| Mar 31, 2022 | -0.17 |
| Dec 31, 2021 | -0.61 |
| Sep 30, 2021 | -0.46 |
| Jun 30, 2021 | 0.09 |
| Dec 31, 2020 | -8.70 |
| Jun 30, 2020 | -7.18 |